Next Article in Journal
Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages
Next Article in Special Issue
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
Previous Article in Journal
Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
Previous Article in Special Issue
Stat3 and Gap Junctions in Normal and Lung Cancer Cells
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(2), 708-722; doi:10.3390/cancers6020708

The Role of STAT3 in Non-Small Cell Lung Cancer

1
Department of Thoracic Oncology, NHO Shikoku Cancer Center, 160 Minami-Umemoto-cho, Matsuyama 791-0280, Japan
2
Department of General Internal Medicine 4, Kawasaki Medical School, 2-1-80 Nakasange, Kita-ku, Okayama 700-8505, Japan
3
Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
*
Author to whom correspondence should be addressed.
Received: 5 December 2013 / Revised: 23 February 2014 / Accepted: 7 March 2014 / Published: 26 March 2014
(This article belongs to the Special Issue STAT3 Signalling in Cancer: Friend or Foe)
View Full-Text   |   Download PDF [495 KB, uploaded 26 March 2014]   |  

Abstract

Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22%~65% of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, such as IL-6, and non-receptor kinases, such as Src. Overexpression of total or phosphorylated STAT3 in resected NSCLC leads to poor prognosis. In a preclinical study, overexpression of STAT3 was correlated with chemoresistance and radioresistance in NSCLC cells. Here, we review the role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC. As STAT3 is a critical mediator of the oncogenic effects of EGFR mutations, we discuss STAT3 pathways in EGFR-mutated NSCLC, referring to mechanisms of EGFR tyrosine kinase inhibitor resistance. View Full-Text
Keywords: signal transducer and activator of transcription 3; Janus kinase 2; epidermal growth factor receptor; non-small cell lung cancer; drug resistance signal transducer and activator of transcription 3; Janus kinase 2; epidermal growth factor receptor; non-small cell lung cancer; drug resistance
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Harada, D.; Takigawa, N.; Kiura, K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers 2014, 6, 708-722.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top